The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT1B/1D receptor agonist
- 8 June 2000
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 398 (1), 73-81
- https://doi.org/10.1016/s0014-2999(00)00240-5
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Migraine with aura shows gadolinium enhancement which is reversed following prophylactic treatment.Cephalalgia, 1998
- Comparison of contractile responses to 5‐hydroxytryptamine and sumatriptan in human isolated coronary artery: synergy with the thromboxane A2‐receptor agonist, U46619British Journal of Pharmacology, 1993
- Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacksNeurology, 1992
- 5-Hydroxytryptamine-induced contractions of the human isolated saphenous vein: involvement of 5-HT2 and 5-HT1D-like receptors, and a comparison with grafted veinsNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1992
- Treatment of Migraine Attacks with SumatriptanNew England Journal of Medicine, 1991
- Further characterization of the putative 5‐HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura materBritish Journal of Pharmacology, 1991
- Role of 5‐HT1‐like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptanBritish Journal of Pharmacology, 1991
- The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura materBritish Journal of Pharmacology, 1990
- 5-hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activationEuropean Journal of Pharmacology, 1989
- The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogsBritish Journal of Pharmacology, 1989